Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a testosterone shot before surgery speed recovery?

NCT ID NCT04731376

Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether giving testosterone replacement therapy to men with low testosterone before and after major urologic surgery is safe and might improve recovery. Researchers will track quality of life, frailty, complications, hospital stay length, and readmissions in 56 participants. The goal is to see if this approach is worth studying further to help patients bounce back faster.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
testosterone cypionate (a form of testosterone given by injection)
What this could lead to
If it works, this could point toward a simple way to help men with low testosterone recover faster and better after major urologic surgery.
What could go wrong
This is a very early, small pilot study (56 people) focused on safety and feasibility, not proof of effectiveness. Testosterone therapy carries risks like worsening prostate issues or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

56 people

The number who actually took part.

Started

Jan 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients already scheduled for major surgery requiring an overnight hospital stay * Patients must be able to give informed consent * Patients must be willing to do study's preoperative and post-operative assessment tools Exclusion Criteria: * Patient with history of prostatectomy with detectable prostate specific antigen (PSA) * Patient with history of prostate radiation/chemotherapy treatment and has experienced bounce or rise in PSA * Patients with history of/undergoing orchiectomy * Patients undergoing hormone replacement therapy currently or history of testosterone use within last year * Patients who use anabolic steroids * Patients with history of solitary or undescended testis * Patients with history of pituitary disorders * Patients with history of thromboembolic events in last year * Patients with hematocrit \> 55% * Patients with uncontrolled congestive heart failure * Special populations: Adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women and prisoners

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypogonadism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm hypogonadism malignant urinary system neoplasm urinary system disorder urinary system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypogonadism Malignant urinary system neoplasm Urinary system disorder Urinary system neoplasm

Contacts and locations

Locations

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.